Keros Therapeutics Q4 EPS $(0.86) Misses $(0.60) Estimate, Sales $3.042M Beat $2.757M Estimate

Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(0.86) per share which missed the analyst consensus estimate of $(0.60) by 42.62 percent. This is a 24.56 percent increase over losses of $(1.14) per share from the same period last year. The company reported quarterly sales of $3.042 million which beat the analyst consensus estimate of $2.757 million by 10.33 percent. This is the same as the same period last year.